Abstract:STAT3 (signal transducer and activator of transcription 3) is a transcription factor and a promising therapeutic target for cancer and other human diseases. In addition to its role in regulation of tumor cells, STAT3 also plays a key role in regulation of immunity and is a promising therapeutic target for the development of new immuno-oncology drugs. Our laboratory has previously reported the development of potent and highly selective STAT3 degraders, including SD-36 and SD-91. Extensive optimization of SD-36 and SD-91 yielded new, highly potent, selective and efficacious STAT3 degraders. In direct comparison, our most potent, new STAT3 degrader (compound 1) is >50-times more potent than SD-36 in inducing STAT3 degradation in cells and demonstrates >500-fold degradation selectivity over other STAT members. A single intravenous administration of compound 1 in mice is highly effective in inducing complete depletion of STAT3 protein in tissues for 48-96 h without reducing the levels of other STAT proteins. Compound 1 is very effective in inhibition of tumor growth not only in tumor models responsive to immune checkpoint blockade (ICB) but also in tumor models resistant to ICB. Furthermore, combination of compound 1 with PD-1/PD-L1 antibodies greatly enhances the antitumor activity as compared to SD-1218 or ICB. Of significance, compound 1 is well tolerated in mice without any signs of toxicity in mice at highly efficacious doses. Our mechanistic studies show that STAT3 depletion has a major effect in modulation of the immune cells in mice. Collectively, our data suggest that selective STAT3 degradation hold great promise for new cancer immunotherapy. Citation Format: Longchuan Bai, Haibin Zhou, Jiajia Zhou, Dimin Wu, Ranjan Kumar Acharyya, Hoda Metwally, Donna McEachern, Bo Wen, Duxin Sun, Weiping Zou, Shaomeng Wang. Evaluation of a highly potent and selective STAT3 degrader as a new class of immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6057.

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression in Vivo.

Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression

Abstract 3881: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression

Abstract 4519: Discovery of highly potent, selective and efficacious STAT3 PROTAC degraders capable of achieving complete tumor regression

Abstract 6057: Evaluation of a highly potent and selective STAT3 degrader as a new class of immunotherapy

Abstract 4509: Discovery of potent and highly efficacious STAT3 PROTAC degraders capable of achieving long-lasting tumor regression

Small-molecule Inhibitors Targeting the DNA-binding Domain of STAT3 Suppress Tumor Growth, Metastasis and STAT3 Target Gene Expression in Vivo

Structure-based Discovery of Potent and Selective Small-Molecule Inhibitors Targeting Signal Transducer and Activator of Transcription 3 (STAT3).

A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion

Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment

Small Molecular Inhibitors and Degraders Targeting STAT3 for Cancer Therapy: an Updated Review (from 2022 to 2024)

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation

Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer

Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation

A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo

Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

Small-molecule PROTAC Mediates Targeted Protein Degradation to Treat STAT3-dependent Epithelial Cancer.

Design, synthesis, and biological evaluation of naphthoylamide derivatives as inhibitors of STAT3 phosphorylation

A Novel Small Molecule, LLL12, Inhibits STAT3 Phosphorylation and Activities and Exhibits Potent Growth-Suppressive Activity in